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A B S T R A C T
Objectives: To develop a clinical prediction rule (CPR) for the diagnosis of pleural tuberculosis (PT) in
patients with pleural exudates in Peru.
Methods: Clinical and laboratory information was collected from patients with exudative pleural effusion
attending two reference hospitals in Lima, Peru. Predictive ﬁndings associated with PT in a multiple
logistic regression model were used to develop the CPR. A deﬁnite diagnosis of PT was based on a
composite reference standard including bacteriological and/or histological analysis of pleural ﬂuid and
pleural biopsy specimens.
Results: A total of 238 patients were included in the analysis, of whom 176 had PT. Age, sex, previous
contact with a TB patient, presence of lymphadenopathy, and pleural adenosine deaminase (ADA) levels
were found to be independently associated with PT. These predictive ﬁndings were used to construct a
CPR, for which the area under the receiver operating characteristics curve (AUC) was 0.92. The single best
cut-off point was a score of 60 points, which had a sensitivity of 88%, speciﬁcity of 92%, a positive
likelihood ratio of 10.9, and a negative likelihood ratio of 0.13.
Conclusions: The CPR is accurate for the diagnosis of PT and could be useful for treatment initiation while
avoiding pleural biopsy. A prospective evaluation is needed before its implementation in different
settings.
© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Pleural tuberculosis (PT) is one of the most common forms of
extrapulmonary TB and a common cause of exudative pleural
effusion in developing countries (Sharma and Mohan, 2004). The
differential diagnosis of exudative pleural effusion includes several
conditions, the most important one being neoplasms with pleural
involvement (Porcel and Vives, 2003). Bacteriological studies of
pleural ﬂuid to conﬁrm the presence of Mycobacterium tuberculosis
have low sensitivity (Gopi et al., 2007), and even molecular tests
are only helpful in a small group of patients (Denkinger et al.,
2014). Consequently, reaching a deﬁnite diagnosis in many cases
requires performing an invasive procedure such as pleural biopsy* Corresponding author at: Escuela de Medicina, Universidad Peruana de Ciencias
Aplicadas, Avenida Alameda San Marcos cuadra 2, Chorrillos, Lima, Peru.
E-mail addresses: lsolari@ins.gob.pe (L. Solari), pcmeasot@upc.edu.pe (A. Soto),
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).or thoracoscopy for histopathological examination. However,
access to these procedures is frequently restricted, particularly
in settings with constrained resources and a high incidence of TB.
Moreover, these procedures are not exempt from complications
such as bleeding or pneumothorax, which, even if infrequent, can
have serious consequences (Cao et al., 2015).
In some high incidence settings, clinical features and pleural
ﬂuid analyses are the only available tools for decision-making. In
alignment with this, guidelines have been issued to standardize
the use of laboratory tests. The World Health Organization (WHO)
proposes ‘coagulation ability of the pleural ﬂuid’ and ‘presence of
mononuclear predominance in pleural ﬂuid’ as parameters
suggesting a diagnosis of PT when assessing a pleural exudate
(WHO, 2007). Locally, Peruvian guidelines do not propose a
structured approach, but instead only consider microbiological
procedures as criteria for the diagnosis of PT (MINSA, 2013).
Although currently not endorsed by the WHO, the use of adenosine
deaminase (ADA) for the diagnosis of extrapulmonary TB andiety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
104 L. Solari et al. / International Journal of Infectious Diseases 69 (2018) 103–107speciﬁcally for PT is supported by several meta-analyses (Morisson
and Neves, 2008; Liang et al., 2008; Greco et al., 2003; Goto et al.,
2003).
Several clinical prediction rules (CPRs) or scores (tools that use
simple clinical and/or laboratory ﬁndings to assess the likelihood
of a condition or to inform a clinical decision) (Laupacis et al.,1997)
have been proposed to guide the diagnosis of PT in different
settings and populations, but most of all in low-incidence
countries (Porcel and Vives, 2003; Antonangelo et al., 2007;
Burgess et al., 1996; De Oliveira et al., 1994; Demirer et al., 2012;
Ghanei et al., 2004; Neves et al., 2007; Porcel et al., 2008). In Latin
America, the only country in which CPRs have been developed is
Brazil (De Oliveira et al., 1994; Neves et al., 2007). Considering the
importance of the setting for the strength of particular predictive
ﬁndings, it would be useful to develop additional CPRs in other
high-incidence Latin American countries, in order to compare the
predictive ﬁndings included and their diagnostic performance.
These local CPRs could constitute an adequate tool to support
clinical decision-making. The objective of this study was to derive a




Clinical information was obtained from patients attending
Hospital Nacional Cayetano Heredia and Hospital Nacional
Hipolito Unanue, two reference hospitals in Lima, Peru, a country
with a TB incidence of 119/100 000 (http://www.who.int/tb/
publications) (WHO, 2016) and a concentrated HIV epidemic. All
adult patients with pleural effusion diagnosed through chest X-ray
or ultrasound, attending the two hospitals between October 2009
and February 2012, were screened using Light’s criteria for pleural
exudates (Light et al., 1972). Those meeting the criteria for pleural
exudates were referred to the pulmonology units for inclusion in
the study until the required sample size was attained.
After giving informed consent, demographic and clinical
information was collected through direct interviews and physical
examination by certiﬁed physicians. Standard blood tests were
performed. Trained pulmonologists performed a thoracentesis and
a blind closed pleural biopsy with an Abrams needle according to
recommended procedures (McLeod et al., 1989). Cell count and
differential, glucose, lactate dehydrogenase (LDH), protein, and
ADA levels (using the Giusti method) in the pleural ﬂuid were
determined.
In addition, Ziehl–Neelsen acid-fast bacillus (AFB) staining,
Gram staining, and cultures for mycobacteria in Ogawa medium
and Mycobacterial Growth Indicator Tube (MGIT) medium, as well
as PCR for M. tuberculosis and cytology for malignant cells were
performed. The pleural biopsy was sent for histopathological
examination and read by certiﬁed pathologists.
The required sample size was 259 participants based on an
estimated accuracy of 80% for the clinical prediction rule, a
precision of 5%, and a conﬁdence level of 95%, and allowing for up
to 5% of missing data.
Reference standard
The diagnosis of PT was based on a composite reference
standard consisting of the following elements: positive AFB or
culture for M. tuberculosis in any of the culture media or positive
PCR for M. tuberculosis (all of these in pleural ﬂuid) or presence of
caseating granulomas in the histopathology of the pleural biopsy,
or histopathological ﬁndings compatible with TB (ﬁbrosis,
lymphocytic inﬁltration, unspeciﬁc granulomas) followed bycomplete resolution of the effusion and all of the clinical symptoms
within the 3 months after initiating anti-TB therapy.
Malignant pleuritis was deﬁned by the presence of malignant
cells in the pleural ﬂuid or biopsy. Other causes of pleural exudate
diagnosed through immunohistochemistry or cultures included
connective tissue diseases and bacterial and fungal infections.
Patients for whom neither the pleural ﬂuid analysis, nor the pleural
biopsy, nor speciﬁc complementary tests allowed a diagnosis to be
reached within 3 months of follow-up, were considered to have
‘pleural exudates of unknown cause’ and were excluded from the
analysis. Diagnostic thoracoscopy could not be performed.
Development of the prediction rule
The aim was to differentiate patients with PT from those with
other pathologies. Predictive ﬁndings that were identiﬁed as
relevant in previously published clinical prediction rules for the
diagnosis of PT, or that had a strong association with TB in general,
were used (Porcel and Vives, 2003; Antonangelo et al., 2007;
Burgess et al., 1996; De Oliveira et al., 1994; Demirer et al., 2012;
Ghanei et al., 2004; Neves et al., 2004; Neves et al., 2007; Porcel
et al., 2000; Porcel et al., 2008; Valdes et al., 2010; Yildiz et al.,
2011). The following were selected as relevant predictive
anamnestic and clinical ﬁndings for evaluation: age (in years),
sex, having had previous contact with a patient with TB (deﬁned as
living in the same dwelling or working in the same area as a person
with a diagnosis of TB during the last 2 years), disease duration
(duration of symptoms in days), and presence of fever (as reported
by the patient, not necessarily conﬁrmed at the examination),
night sweats, haemoptysis, and lymphadenopathy (presence of
lymph nodes at any site, observed by the patient or detected during
physical examination). The laboratory predictive ﬁndings that
were withheld were the white blood cell count, pleural protein,
pleura/serum protein ratio, pleural LDH, percentage of lympho-
cytes in pleural cells, and pleural ADA.
Univariate logistic regression was performed to assess the
association of the predictor variables with PT. Those predictors
found to be associated with an odds ratio (OR) >2 or <0.5 and/or a
p-value of <0.10 were retained and used to develop a multiple
logistic regression model. Variables with the highest p-values were
dropped from the full model in a backward fashion until only
variables with a p-value of <0.05 were kept. A bootstrapped linear
regression of the expected individual PT probabilities (based on the
ﬁnal logistic regression model) on the withheld variables was then
performed. The beta coefﬁcients for the predictors in this linear
regression model were multiplied by 100 and rounded to the
nearest integer to assign the speciﬁc number of points for each
predictor in the ﬁnal score.
The objective for deﬁning the cut-off point of the score was to
reach a positive likelihood ratio (LR) of 10 or a negative LR of 0.1.
These values are considered adequate for diagnostic purposes
(Deeks, 2004). If no single cut-off point fulﬁlled this objective,
three categories were to be deﬁned: low likelihood of PT for those
scores with a negative LR of 0.1, high likelihood of PT for those
scores with a LR of 10, and intermediate likelihood for the scores
in between.
The sensitivity, speciﬁcity, predictive values, and LRs of the
score were calculated for the selected cut-off point(s). Additionally
a receiver operating characteristics (ROC) curve analysis was used,
and the area under the ROC curve (AUC) for the score was
compared to that for pleural ADA alone. All calculations were
performed using STATA version 11 for Windows (StataCorp.,
College Station, TX, USA).
Written informed consent was obtained from all participants.
The study was approved by the ethics committees of Universidad
Peruana Cayetano Heredia, Hospital Nacional Cayetano Heredia,
Table 1
Clinical and laboratory predictive ﬁndings and their association with pleural tuberculosis in the univariate and multiple logistic regression models; Lima, Peru.
Predictive ﬁndings Patients Univariate logistic
regression






OR (95% CI) p-Value OR (95% CI) p-Value
Clinical
Mean age, years (95% CI) 37.1 (34.4–39.8) 61.9 (56.6–64.6) 0.94 (0.92–0.96) <0.001 0.96 (0.94–0.98) <0.001
Mean disease duration, days (95% CI) 35 (33–37) 77 (74–82) 0.90 (0.85–0.95) <0.001 Not withheld in the ﬁnal model
Fever % (95% CI) 81 (74–86) 45 (32–58) 5.07 (2.71–9.47) <0.001 Not withheld in the ﬁnal model
Male % (95% CI) 70 (66–80) 45 (32–58) 2.90 (1.60–5.25) <0.001 2.77 (1.16–6.67) 0.02
Contact with a patient with TB % (95% CI) 50 (42–58) 23 (13–25) 3.43 (1.76–6.66) <0.001 3.25 (1.30–8.07) 0.01
Night sweats % (95% CI) 60 (53–68) 34 (22–47) 2.96 (1.61–5.42) <0.001 Not withheld in the ﬁnal model
Haemoptysis % (95% CI) 7 (4–12) 15 (7–26) 0.43 (0.17–1.08) <0.07 Not withheld in the ﬁnal model
Lymphadenopathy % (95% CI) 16 (11–22) 32 (21–45) 0.40 (0.20–0.78) <0.01 0.18 (0.06–0.56) 0.003
Laboratory
Mean WBC count in blood, 109/l (95% CI) 7.750 (7.267–8.232) 8.525 (7.642–9.409) 0.99 (0.99–1.00) 0.11 Not considered for inclusion in the
model
Mean proteins in pleural ﬂuid, g/dl (95% CI) 5.16 (5.03–5.29) 4.16 (3.83–4.49) 2.53 (1.79–3.57) <0.001 Not withheld in the ﬁnal model
Pleural/serum protein ratio (95% CI) 0.58 (0.53–0.62) 0.61 (0.54–0.68) 0.67 (0.24–1.89) 0.49 Not considered for inclusion in the
model
Mean LDH in pleural ﬂuid, g/dl (95% CI) 880.2 (809.1– 951.4) 866.9 (553.2–1180.6) 1.00 (1.00–1.00) 0.90 Not considered for inclusion in the
model
Mean lymphocyte proportion in pleural ﬂuid (95% CI) 63 (58–68) 67 (61–74) 0.66 (0.25–1.72) 0.40 Not considered for inclusion in the
model
Mean ADA in pleural ﬂuid, U/l (95% CI) 79.2 (73.7–84.6) 28.0 (19.9–36.1) 1.06 (1.04–1.07) <0.001 1.05 (1.03–1.06) <0.001
TB, tuberculosis; OR, odds ratio; CI, conﬁdence interval; WBC, white blood cell; LDH, lactate dehydrogenase; ADA, adenosine deaminase.
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Results
Three hundred and eighty-three patients were eligible for
inclusion in the study. Of these, 101 did not consent to participate
and a further 41 were excluded: 21 because a deﬁnite diagnosis
could not be reached, 12 had empyema, and eight had incomplete
data for analysis. Three had concomitant evidence of TB and
malignancy. Of the 238 patients eventually included in the
analysis, 176 had a diagnosis of PT. One hundred and forty were
conﬁrmed through microbiology or the presence of caseating
granulomas on histopathology and 36 were diagnosed through
histopathological ﬁndings compatible with TB followed by
complete resolution of the symptoms after treatment. Sixty-two
had other causes of pleural exudates, out of which 50 were
neoplastic, seven were associated with connective tissue diseases,
three had a bacterial aetiology, and two had a fungal origin.
The mean age of the 238 included patients was 43.6 years (95%
conﬁdence interval (CI) 40.9–46.3 years). One hundred and ﬁfty-
two (64%) were male, 28 (12%) had a previous history of TB, and 102
(43%) reported having had contact with a patient with TB. The
mean duration of symptoms was 46.3 days (95% CI 39.0–53.6 days).
Fourteen (6%) of the tested patients were infected with HIV (12
patients refused testing).Table 2
Clinical prediction rule (score) for pleural tuberculosis; Lima, Peru.
Offset +70
Predictive ﬁndings
Age in years 0.7  (number of years)
Sex (male) +12
Contact with a patient with TB (presence of) +13
Lymphadenopathy (presence of) 19
ADA in IU/l +0.4  (ADA)
TB, tuberculosis; ADA, adenosine deaminase.The univariate logistic regression analysis found that age, sex,
contact with a patient with TB, duration of illness, fever, night
sweats, hemoptysis, lymphadenopathy, ADA, and proteins in the
pleural ﬂuid were associated with PT at a p-value of 0.10 (Table 1).
After developing the multiple logistic regression model, only age,
sex, contact with a TB patient, lymphadenopathy, and pleural ADA
remained signiﬁcantly and independently associated with PT at a
p-value of 0.05. The corresponding ORs and individual p-values
are shown in Table 1.
Table 2 shows the ﬁnal CPR and the number of points assigned
to each predictive ﬁnding.
Figure 1 shows the scores that patients with PT and those with
other conditions obtained with the application of this CPR.
Based on the ROC curve analysis, the best single cut-off point for
the score was 60 points and for ADA was 30 IU/l (Figure 2). This
cut-off point for the score had an overall accuracy (patients
correctly classiﬁed) of 89.1%, a sensitivity of 88.1% (95% CI 82.3–
92.5%), a speciﬁcity of 91.9% (95% CI 82.2–97.3%), a positiveFigure 1. Scores in patients with pleural tuberculosis and in those with other
conditions.
Figure 2. ROC curves for the clinical prediction rule developed and for adenosine
deaminase.
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value of 73.1% (95% CI 64.4–80.3%), a positive LR of 10.92 (95% CI
4.7–25.4), and a negative LR of 0.13 (95% CI 0.09–0.2).
In spite of coming close, this single best cut-off point did not
simultaneously attain a positive LR >10 and a negative LR <0.1.
Deﬁning an additional cut-off point at 53 points and moving the
higher cut-off to 62 points instead of 61 points, allowed the
patients to be categorized as having a high, medium, or low
probability of having PT. In patients scoring 62, the condition
would be ‘ruled in’. In patients scoring 53, the CPR attained a
sensitivity of 93%, a negative LR of 0.08, and a negative predictive
value of 94%, which would allow PT to be ‘ruled out’. With this
approach, 26% were classiﬁed as having a low probability of PT and
67% of patients as having a high probability of PT, and these
patients could be managed accordingly.
Discussion
A CPR for PT was developed based on anamnestic ﬁndings,
clinical symptoms, and ADA levels, in a simple pleural ﬂuid
analysis. This CPR attained an overall accuracy of 89% and AUC of
0.92, indicating a good diagnostic performance in this study
population. It constitutes a simple and affordable tool for the
diagnosis of PT, allowing correct decision-making in most patients
in the present study population.
However, although the score had a fair overall accuracy, no
single cut-off point achieved high positive and negative LRs
simultaneously. The negative predictive value of the best single
cut-off point would be too low for decision-making. The approach
using two cut-off points is more interesting in terms of clinical
utility. This CPR, which is intended for use in high-incidence,
resource-constrained settings, could then guide the initiation of
anti-TB treatment in patients with a high probability of PT, without
the need to perform a pleural biopsy. Likewise, in patients with a
low probability of PT, further diagnostic work-up could be directed
towards other diagnoses, particularly neoplasms.
Several CPRs have already been derived for the diagnosis of
pleural TB, but most of them have been investigated in settings that
differ signiﬁcantly from Latin America in general and Peru in
particular, a country with a high incidence of TB and a concentrated
HIV epidemic. CPRs are usually context-speciﬁc, and it was
considered relevant to develop a local CPR and to compare the
predictive ﬁndings it included with those of other CPRs. The
predictive ﬁndings in the present study were found to be
consistent, at least in part, with those used in several other CPRs.Among the variables included, male sex and contact with a TB
patient were positively associated with PT. Age had a negative
association with PT, as found in many other studies (Porcel and
Vives, 2003; Antonangelo et al., 2007; Demirer et al., 2012): PT was
more likely to be present in younger patients and conversely
malignancy was more frequent in older patients. Lymphadenopa-
thy was also found to be negatively associated with PT, as it was
found more often in cases of pleural effusion associated with
neoplastic metastatic disease with lung and lymphatic involve-
ment.
Of note, ADA activity was the only pleural ﬂuid analysis, and
even laboratory ﬁnding, associated with PT. Pleural protein and in
particular the percentage of lymphocytes in pleural cells, which is a
predictive ﬁnding included in several CPRs (Sales et al., 2009), was
not independently associated with PT in the present study
patients. Since M. tuberculosis-induced lymphocytic activation is
the main mechanism for ADA generation, the predictive ability of
lymphocytes may be limited when ADA levels have already been
taken into consideration. With respect to the protein levels, this
study population consisted of patients with pleural exudates, so its
discriminatory power was not expected to be high. Currently, one
of the few available recommendations on tuberculous pleuritis
suggests strongly taking into account the results of pleural ﬂuid
analyses when determining the diagnosis (Light, 2010).
It is also of note that this CPR performed better than ADA alone
(7% more sensitive and 5% more speciﬁc). This is in contrast with
earlier ﬁndings (Solari et al., 2017), possibly because the present
study made comparisons using a locally derived CPR instead of an
external one. The former perform better than those developed in
different epidemiological settings, as the strength of association
between the predictive ﬁndings and PT varies.
A limitation of this study is the quite high proportion of patients
who could not be included due to refusal of the pleural biopsy. In
addition, the possible contribution of molecular tools as potential
predictive ﬁndings, in particular of GeneXpert and interferon
gamma release assays (IGRAs), was not evaluated. In principle,
CPRs should only include results from anamnesis, physical
examination, and simple tests, and both of these tests are
considered high complexity ones by the food and drug adminis-
tration clinical laboratory improvement amendments FDA-CLIA
(FDA, 2018). Their availability in hospitals in resource-constrained
settings such as ours is very limited. Furthermore, evidence on
their utility for PT is still being debated. Recent papers have failed
to provide conclusive evidence concerning the diagnostic accuracy
of GeneXpert for PT (Denkinger et al., 2014), and a systematic
review showed suboptimal performance of IGRAs in the diagnosis
of PT (Aggarwal et al., 2015). More recently, the measurement of
serum and pleural interleukins such as IL-31 (Gao et al., 2016) has
shown sensitivities and speciﬁcities over 90% for the diagnosis of
pleural TB, but once more these are high complexity tests that need
further evaluation.
In conclusion, the CPR derived in this study is a useful tool for
the diagnosis of PT. As is this case for every CPR, it requires further
validation before being implemented, particularly in different
settings. In Peru, it could be used immediately as a tool for
decision-making in patients with pleural exudates and would
allow the management of such patients to be standardized,
avoiding invasive procedures, preventing their complications, and
saving resources.
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